The purpose of this study is to assess the relationship between bupropion, stimulant use and
relapse, ADHD (Attention Deficit Hyperactivity Disorder), and measures of mood, drug craving,
and inhibitory control in individuals enrolled in inpatient treatment for stimulant-use
disorder with and without ADHD.
The experimenters hypothesize that Bupropion and Contrave (Bupropion/Naltrexone) will
increase inhibitory control and decrease drug craving and depressive symptoms in recently
abstinent stimulant users in inpatient treatment with effects greater than those seen in
recently abstinent stimulant users completing inpatient treatment as usual. An additional
hypothesis is that relapse rates after leaving inpatient treatment in the group receiving
bupropion will be lower than those of the group completing inpatient treatment as usual.
The study design consists of four assessments of drug craving, inhibitory control, impulsive
choice, and mood (depression and anxiety). The timepoints for these assessments include: A.
baseline after entering treatment B. 2 weeks after starting drug C. 8 weeks after starting
drug, and D. 1 month after leaving treatment. Following eligibility screening, 60 stimulant
users will be enrolled in one of 3 groups. Group 1 Bupropion Active Group: 20 subjects will
receive bupropion for 8 weeks during inpatient treatment. Group 2 Contrave Active Group: 20
subjects will receive Contrave for 8 weeks during inpatient treatment. Group 3 Control Group:
20 subjects enrolled in inpatient treatment will complete treatment as usual as well as the
four assessments (A-D) described above but will not receive drug (convenience control). Half
of the subjects in each group will be diagnosed with ADHD and half will not, for a total of
10 subjects per group with ADHD.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of California, Los Angeles
Treatments:
Bupropion Bupropion hydrochloride, naltrexone hydrochoride drug combination Naltrexone